Quality of Life in Renal Cell Carcinoma Patients Undergoing Home Therapy
Author Information
Author(s): J Atzpodien, Th Küchler, T Wandert, M Reitz
Primary Institution: Medizinische Hochschule Hannover
Hypothesis
Patients with more intact immune functions may experience a deterioration in their quality of life during IL-2-based therapy.
Conclusion
The study found that low-dose immunotherapy significantly reduced patients' quality of life shortly after treatment initiation.
Supporting Evidence
- Patients' mean global-quality-of-health scale deteriorated significantly from 64 to 41.
- Physical functioning decreased from 82 to 65, emotional functioning from 77 to 61, and social functioning from 78 to 55.
- Symptoms such as appetite loss, fatigue, and nausea/vomiting significantly increased during treatment.
Takeaway
This study looked at how patients with kidney cancer felt during treatment at home, and it showed that many felt worse after starting therapy.
Methodology
Patients completed the EORTC QLQ-C30 questionnaire before and three weeks after starting treatment to assess quality of life.
Potential Biases
Potential bias in patient selection due to the requirement for good performance status.
Limitations
The study only assessed quality of life at two time points and did not evaluate long-term effects.
Participant Demographics
16 male and 6 female patients, median age 64 years, with a range of 45 to 74 years.
Statistical Information
P-Value
p≤0.001
Statistical Significance
p≤0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website